Skip to Content
 

News: Urologic Cancers

Rathmell receives 2019 Eugene P. Schonfeld Award

Wednesday, November 6th, 2019

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.

Urologic cancer expert Rini joins VICC as chief of Clinical Trials

Thursday, October 24th, 2019

Brian Rini, MD, an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development, is joining Vanderbilt-Ingram Cancer Center as the inaugural chief of Clinical Trials.

Research summit to highlight genitourinary cancer advances

Thursday, October 24th, 2019

Some of the nation’s leading genitourinary cancer physicians will speak about the latest advances in care at an OncLive State of the Science Summit held in collaboration with Vanderbilt-Ingram Cancer Center.

Potential prostate cancer biomarkers

Thursday, September 19th, 2019

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

Hand-held robot points to less invasive prostate surgery

Friday, July 19th, 2019

Vanderbilt collaborators focused on minimally invasive prostate surgery are developing an endoscopic robotic system with two-handed dexterity at a much smaller scale than existing options.

VISE team seeks to develop new robot to ease prostatectomies

Thursday, April 25th, 2019

The Vanderbilt Institute for Surgery and Engineering (VISE) team of Robert Webster III, PhD, and Duke Herrell, MD, have received a $2.2 million grant from the National Institutes of Health to develop a new surgical robot for endoscopic transurethral prostatectomy.

Society of Urologic Oncology honors Smith’s contributions

Thursday, April 4th, 2019

Joseph “Jay” Smith Jr., MD, professor of Urologic Surgery, has been awarded the 2019 Willet F. Whitmore Jr. Award and Lectureship from the Society of Urologic Oncology (SUO).

Achilles’ heel for kidney cancer

Monday, March 4th, 2019

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Society of Urologic Oncology honors Barocas’ contributions

Monday, February 4th, 2019

Daniel Barocas, MD, MPH, associate professor of Urology, is being recognized with a national award from the Society of Urologic Oncology (SUO) for his efforts to develop urologic cancer quality measures.

Therapy aims to reduce prostate cancer treatment side effects

Friday, December 14th, 2018

Vanderbilt urologic surgeons are offering an alternative therapy for prostate cancer patients considered to be low-to-intermediate risk, a middle ground between active surveillance and aggressive therapy.

Next Page »